Training QA and Manufacturing on When to Involve RA Early Training QA and Manufacturing on When to Involve RA Early The intersection of Quality Assurance (QA), Manufacturing, and Regulatory Affairs (RA) is critical in ensuring compliance and achieving successful regulatory submissions. The integration of GxP quality systems with regulatory affairs enhances product quality and accelerates the regulatory approval process. This article serves as a comprehensive manual on the expectations and structures surrounding regulatory affairs and compliance, particularly focusing on when and how to involve Regulatory Affairs early in the product lifecycle. Regulatory Affairs Context Regulatory Affairs is a critical function…

Building Dashboards that Combine Quality and Regulatory Risk Indicators Building Dashboards that Combine Quality and Regulatory Risk Indicators In an increasingly regulated environment, the integration of Quality Management Systems (QMS) with Regulatory Affairs (RA) practices is essential for pharmaceutical and biotechnology organizations. This article discusses how to effectively build dashboards that incorporate both quality and regulatory risk indicators, specifically focusing on pharmacovigilance as a key area of integration. Regulatory Affairs Context Regulatory Affairs is integral to the pharmaceutical and biotechnology sectors, as it ensures compliance with applicable regulatory frameworks in the US, UK, and EU. A crucial aspect of RA…

Managing Product Holds, Recalls and Shortages Through Joint QA–RA Processes Managing Product Holds, Recalls and Shortages Through Joint QA–RA Processes Context In the pharmaceutical and biotechnology sectors, the convergence of Quality Assurance (QA) and Regulatory Affairs (RA) is essential for ensuring the safety, efficacy, and quality of healthcare products. The integration of GxP quality systems with regulatory frameworks is a critical aspect of this alignment, particularly when managing product holds, recalls, and shortages. These processes not only preserve product integrity and patient safety but also ensure compliance with regulatory expectations from agencies such as the FDA, EMA, and MHRA. Legal/Regulatory…

How to Ensure Change Histories Are Visible in Dossiers and eCTD Sequences How to Ensure Change Histories Are Visible in Dossiers and eCTD Sequences In the evolving landscape of pharmaceutical regulation, the integration of Quality Management Systems (QMS) with Regulatory Affairs (RA) is increasingly crucial. Understanding how to maintain and present change histories in regulatory submissions, particularly within the context of electronic Common Technical Document (eCTD) sequences, is vital for compliance during regulatory inspections and audits. Regulatory Context Regulatory Agencies such as the FDA, EMA, and MHRA require detailed documentation of changes throughout the lifecycle of a product. Ensuring that…

Auditing the Interface Between QMS, PV and RA for Weak Links Auditing the Interface Between QMS, PV and RA for Weak Links Context In the pharmaceutical and biotech sectors, the integration of Quality Management Systems (QMS) with Regulatory Affairs (RA) is critical for ensuring compliance and maintaining standards across all operations. Regulatory agencies such as the FDA, EMA, and MHRA require robust processes that connect various departments, including Clinical, Quality Assurance (QA), Pharmacovigilance (PV), and Commercial functions. This article aims to elucidate the interaction between QMS, PV, and RA, highlighting common deficiencies and offering practical strategies for ensuring compliance. Legal/Regulatory…

Change Control for Labelling, Artwork and Safety Text: QMS Touchpoints Change Control for Labelling, Artwork and Safety Text: QMS Touchpoints Integration between Quality Management Systems (QMS) and Regulatory Affairs (RA) is a fundamental requirement for pharmaceutical companies. Effective change control processes surrounding labelling, artwork, and safety texts are critical touchpoints that intersect with pharmacovigilance systems and GxP quality systems. This regulatory explainer manual guides regulatory professionals through the essential regulations, guidelines, documentation requirements, and agency expectations pertaining to change control in GxP environments with a focus on compliance and audit readiness. Context Change control refers to a systematic approach to…

Governance Committees Where QA and RA Co-Own Decisions Governance Committees Where QA and RA Co-Own Decisions In the pharmaceutical and biotechnology sectors, regulatory compliance is paramount to ensuring product safety, efficacy, and quality. Governance committees that integrate quality assurance (QA) and regulatory affairs (RA) play a critical role in fostering collaboration towards achieving regulatory compliance. This article serves as a comprehensive manual for professionals in Regulatory Affairs, Quality Assurance, and related fields who are navigating the complexities of GxP quality systems, deviations, corrective and preventive actions (CAPA), and change control processes. Context The integration of QA and RA is essential…

Designing SOPs That Reflect Real Information Flows to RA Designing SOPs That Reflect Real Information Flows to RA Context The integration of regulatory affairs (RA) with quality management systems (QMS) is essential for ensuring compliance with Good Practice (GxP) regulations across the pharmaceutical and biotech industries. Effective Standard Operating Procedures (SOPs) form the backbone of this integration, as they dictate the flows of information between various functions—including RA, Quality Assurance (QA), Quality Control (QC), Clinical, and Commercial teams. In this article, we will explore how to design SOPs that facilitate seamless communication and compliance, allying RA with operational excellence. Legal/Regulatory…

Remediation Programs Focused on Fixing QA–RA Disconnects Remediation Programs Focused on Fixing QA–RA Disconnects In the complex landscape of pharmaceutical development and manufacturing, the interplay between Quality Assurance (QA) and Regulatory Affairs (RA) is critical. When these functions operate in silos, the potential for miscommunication and regulatory non-compliance increases significantly. This article explores the integration of QA and RA within the framework of GxP quality systems, focusing on remediation programs aimed at addressing QA–RA disconnects. Regulatory and compliance consulting plays a vital role in this integration, particularly in navigating regulatory inspections and audits across the US, UK, and EU. Context…

Future State: Fully Connected QMS, RIM and Regulatory Operations Ecosystems Future State: Fully Connected QMS, RIM and Regulatory Operations Ecosystems The landscape of pharmaceutical development and regulatory compliance is continually evolving, necessitating seamless integration between Quality Management Systems (QMS), Regulatory Information Management (RIM), and broader Regulatory Affairs (RA) operations. This article serves as a comprehensive regulatory explainer manual for professionals within Regulatory Affairs, CMC, and Labelling teams across the US, UK, and EU, addressing critical aspects of integrating GxP quality systems with regulatory operational frameworks. Context Quality assurance and regulatory affairs are vital components of pharmaceutical development that ensure safety,…